Phase 2 Evidence and Impact Analysis
Article 1 — Portal Vein Thrombosis: INASL Recommendations (PMID: 43001267)
🟢 NEAR_TERM_IMPLEMENTABLE | Narrative Review | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Guidance synthesis, not new discovery; heterogeneity in PVT management justifies the update |
| Clinical Relevance | 7 | Expert consensus recommendations directly inform clinical decisions across hepatology practice |
| Population Reach | 5 | PVT is common in cirrhosis (affecting ~15–20% of cirrhotic patients globally), significant burden in South/Southeast Asia |
| Implementation Speed | 7 | Guidelines can be adopted immediately upon publication; no regulatory pathway needed |
| Evidence Strength | 3 | Narrative review with expert opinion; no primary data, no graded evidence synthesis described |
- Key quantitative result: None reported — expert opinion and narrative synthesis
- External validation: None; expert consensus only
- Main limitation: Paucity of RCT-level evidence in PVT; recommendations rely heavily on expert opinion, increasing risk of bias
- Equity implications: Developed for Indian patients — well-suited to a large, underserved population; may have limited direct applicability to Western or other Asian contexts without adaptation
- Evidence Maturity (revised): Exploratory (confirmed — narrative review with expert opinion)
Article 2 — Validation of IST80 Plus ctDNA Panel for Advanced NSCLC (PMID: 43001313)
⬜ Standard | Validation Study | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ctDNA profiling panels are increasingly established; IST80 Plus extends existing Illumina technology with fusion detection capability |
| Clinical Relevance | 7 | NSCLC genomic profiling from plasma is now clinically essential; validated panels directly enable treatment selection |
| Population Reach | 7 | NSCLC is the leading cause of cancer death worldwide; plasma-based profiling could benefit hundreds of thousands annually |
| Implementation Speed | 6 | Commercially supported platform; regulatory clearance and lab integration are the main near-term barriers |
| Evidence Strength | 6 | Multi-material validation with clinical plasma samples from characterized NSCLC; limited by small clinical cohort (n=18 patients) and abstract-only access |
- Key quantitative result: High sensitivity for small variants at 0.5% allele frequency; reliable fusion detection (specific metrics not available from abstract)
- External validation: External quality assessment samples (n=6) included — partial external validation
- Main limitation: Small clinical patient cohort (n=18); no head-to-head comparison with tissue biopsy or competing liquid biopsy panels
- Equity implications: Benefits patients who cannot safely undergo repeat tissue biopsy; broader access depends on cost and lab infrastructure availability in lower-resource settings
- Evidence Maturity (revised): Validated (confirmed — analytical and clinical validation demonstrated)
Article 3 — Plasma Proteomic Frailty Signature for Cardiovascular Risk (PMID: 43001318)
⬜ Standard | Multi-Cohort Validation Study | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Proteomics-derived frailty index is a meaningful advance over clinical frailty scales; cross-cohort validation adds credibility |
| Clinical Relevance | 7 | Heart failure risk stratification using blood-based frailty signatures could refine prevention and monitoring in older adults |
| Population Reach | 8 | Frailty and heart failure together affect tens of millions globally; Chinese and UK Biobank validation spans diverse populations |
| Implementation Speed | 4 | Proteomic assays are not yet routine clinical tools; clinical translation requires platform standardization and health-economic evidence |
| Evidence Strength | 7 | Large, multi-cohort validation (n=4,323 + n=84,276); prospective UK Biobank component; Cox regression models with incident outcomes |
- Key quantitative result: Plasma frailty (PF) signature showed incremental discrimination for heart failure over standard frailty measures (specific C-statistic/NRI not available from abstract)
- External validation: Yes — validated in two independent cohorts including UK Biobank (n=84,276)
- Main limitation: Proteomic signature composition and clinical cutoffs not disclosed in abstract; translation to routine care requires commercial assay development
- Equity implications: UK Biobank sample is predominantly European; XiDu2017 cohort is Chinese — good for demonstrating cross-ethnic generalizability, but other populations (South Asian, African, Latin American) unrepresented
- Evidence Maturity (revised): Validated (confirmed — dual-cohort prospective validation with large N)
Article 4 — cfDNA Fragmentomics for Preoperative Ovarian Cancer Discrimination (PMID: 43002351)
🔴 EARLY_CANCER_DETECTION | Multicenter Diagnostic Validation | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | cfDNA fragmentomics applied to ovarian cancer triage is relatively new; complementing ROMA algorithm is a meaningful clinical advance |
| Clinical Relevance | 8 | Ovarian cancer has very poor early-detection outcomes; identifying cancers missed by CA125/HE4 addresses a critical gap |
| Population Reach | 6 | ~300,000 new ovarian cancer cases/year globally; broader reach via discriminating benign from malignant pelvic masses in millions of women |
| Implementation Speed | 4 | Multicenter validation is promising but low-pass WGS is not yet routine clinical infrastructure; regulatory and workflow barriers remain |
| Evidence Strength | 6 | Multicenter study with n=743 across multiple cohorts including external test; medium confidence due to abstract-only access and no prospective surgical outcome follow-up described |
- Key quantitative result: cfDNA model detected cancers with CA125 and/or HE4 below conventional thresholds; complementary to ROMA algorithm (specific AUC/sensitivity not available from abstract)
- External validation: External test cohort included; multicenter design
- Main limitation: Exploratory cohorts mentioned suggest prospective clinical utility not yet established; no reported specificity figures that would affect surgical triage decisions
- Equity implications: Ovarian cancer disproportionately diagnosed at late stage in lower-resource settings; a blood-based diagnostic could benefit underserved populations IF cost and infrastructure barriers are addressed
- Evidence Maturity (revised): Exploratory (confirmed — multicenter validation but clinical utility not yet prospectively established)
Article 5 — daNIS-2: Phase III Anti-TGF-β in Metastatic Pancreatic Cancer (PMID: 43002828)
⬜ Standard | Phase III RCT | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | TGF-β blockade in pancreatic cancer was a credible hypothesis; negative Phase III results have high informational value |
| Clinical Relevance | 8 | Definitively closes a therapeutic avenue for mPDAC; directly prevents adoption of an ineffective and potentially harmful treatment |
| Population Reach | 6 | mPDAC affects ~500,000 people/year globally; median survival <12 months — negative trial findings matter urgently |
| Implementation Speed | 9 | Negative trial: immediate clinical impact — NIS793 combination should not be adopted |
| Evidence Strength | 8 | Phase III, randomized, double-blind design; gold standard for efficacy evidence; note: n=21 in abstract metadata appears to be a data extraction error — Phase III trials of this design typically enroll hundreds |
- Key quantitative result: NIS793 + SOC did not improve survival vs. placebo + SOC; associated with unfavorable benefit-risk profile (specific HR/OS data not available from abstract)
- External validation: Phase III RCT is itself the definitive validation
- Main limitation: Abstract-only access; sample size field (n=21) appears incorrect for a Phase III trial — likely a metadata error; full data needed to characterize toxicity profile and any biomarker subgroups
- Equity implications: Pancreatic cancer disproportionately affects older adults; global impact as mPDAC carries near-universal poor prognosis regardless of geography
- Evidence Maturity (revised): Validated (confirmed — Phase III RCT; negative result is definitive within its scope)
Article 6 — 10-Year Cardiovascular/Kidney/Metabolic Risk Models in Prediabetes (PMID: 43003407)
⬜ Standard | Validation Study | Triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Risk prediction models for prediabetes exist; novelty lies in Chinese population focus and dual biomarker (HbA1c vs FPG) comparison |
| Clinical Relevance | 7 | Prediabetes affects ~720 million adults globally; validated risk models for CVD/kidney/metabolic outcomes in frontline care are actionable |
| Population Reach | 8 | Prediabetes is a global epidemic; model validated in Hong Kong Chinese population with potential regional applicability |
| Implementation Speed | 6 | HbA1c/FPG-based tools are already in routine use; risk model adoption depends on electronic health record integration and guideline endorsement |
| Evidence Strength | 6 | Validation study design; abstract-only access limits assessment of cohort size, C-statistics, and calibration details |
- Key quantitative result: HbA1c- and FPG-based models showed comparable 10-year discriminative performance for CVD/kidney/metabolic outcomes
- External validation: Validation study design (training and validation implied); details limited
- Main limitation: Developed in Chinese patients in Hong Kong — may not generalize to other ethnic groups or health systems; no reported NRI/IDI or head-to-head vs. existing tools
- Equity implications: Explicitly developed for Asian populations often underrepresented in Western risk tools; could improve prevention in a large, underserved demographic
- Evidence Maturity (revised): Validated (confirmed — validation study design)
Article 7 — ctDNA MRD Monitoring in Head and Neck Squamous Cell Carcinoma (PMID: 42999361)
⚪ PROMISING_PRELIMINARY | Unspecified Design | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ctDNA MRD is well-established in several cancers; application to HNSCC post-definitive therapy is an active but not entirely novel area |
| Clinical Relevance | 7 | MRD positivity predicting recurrence after definitive HNSCC treatment could directly guide surveillance intensity and salvage timing |
| Population Reach | 5 | ~900,000 HNSCC cases/year globally; most diagnosed at advanced stages |
| Implementation Speed | 4 | Clinical adoption requires validated commercial assay, standardized MRD thresholds, and evidence that MRD-guided intervention improves outcomes |
| Evidence Strength | 4 | Study design unspecified; abstract-only access; medium classification confidence limits scoring |
- Key quantitative result: ctDNA MRD positivity post-treatment associated with disease recurrence and poor survival (quantitative HR not available)
- External validation: Not reported
- Main limitation: Design unspecified — cannot assess rigor; MRD-guided intervention trials not yet reported
- Equity implications: HPV-positive HNSCC (younger, often non-smoking patients) vs. HPV-negative (older, tobacco/alcohol-exposed) represent distinct biological and socioeconomic populations with different prognoses
- Evidence Maturity (revised): Exploratory (downgraded from Validated — study design unknown, insufficient information to confirm validation)
Article 8 — GABBR1 as Cuproptosis-Regulated Prognostic Biomarker in Pancreatic Cancer (PMID: 42999371)
⚪ PROMISING_PRELIMINARY | Bioinformatic Validation | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Cuproptosis is an emerging cell-death mechanism; GABBR1 as a regulator is a genuinely novel mechanistic finding |
| Clinical Relevance | 3 | Preclinical/bioinformatic study; no clinical data; translation to pancreatic cancer therapy is very early stage |
| Population Reach | 4 | Pancreatic cancer is devastating and common (500,000 cases/year); but clinical relevance is too distant to score higher |
| Implementation Speed | 2 | 10+ years from bioinformatic discovery to clinical application |
| Evidence Strength | 4 | scRNA-seq + TCGA analysis — bioinformatic validation only; no functional experiments described; species listed as "unknown" |
- Key quantitative result: GABBR1 modulation reshapes cuproptosis and apoptotic sensitivity; immune microenvironment modulated (quantitative data not available)
- External validation: Public dataset validation (GSE212966 + TCGA-PAAD)
- Main limitation: Entirely computational; no wet-lab functional validation; no clinical data; species/model system unclear
- Equity implications: Minimal at this stage — preclinical discovery
- Evidence Maturity (revised): Exploratory (downgraded from Validated — bioinformatic analysis only)
Article 9 — BMI and Ramadan Fasting in Type 2 Diabetes (DaR Global Survey) (PMID: 42999643)
⚪ PROMISING_PRELIMINARY | Survey Study | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Ramadan fasting safety in T2DM is well-studied; BMI-stratified analysis in a global survey adds detail but limited novelty |
| Clinical Relevance | 6 | Directly relevant to Muslim patients with T2DM and their healthcare providers; large global Muslim diabetic population |
| Population Reach | 7 | ~150 million Muslims with T2DM fast during Ramadan annually; study spans Muslim-majority countries |
| Implementation Speed | 7 | Findings directly inform clinical counseling with no regulatory barriers |
| Evidence Strength | 5 | Large sample (n=6,530) but survey design with self-report bias; species listed as "unknown" is a metadata artifact |
- Key quantitative result: No significant differences in adverse events across BMI categories during fasting; obesity associated with higher BP, hyperlipidemia, microalbuminuria
- External validation: Multi-country survey design provides geographic breadth but not formal external validation
- Main limitation: Self-reported fasting behavior and adverse events; selection bias (survey respondents may not represent all fasting T2DM patients)
- Equity implications: Explicitly addresses Muslim-majority, lower-middle-income country populations — an underrepresented group in diabetes research
- Evidence Maturity (revised): Validated (confirmed — large multinational survey with consistent findings)
Article 10 — Rare Cancer Outcomes with Dual Checkpoint Inhibitors (NCI/SWOG S1609) (PMID: 42999803)
⚪ PROMISING_PRELIMINARY | Retrospective Observational | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Liver/lung metastasis impact on ICI outcomes is known in common cancers; extending this to rare tumors is a meaningful contribution |
| Clinical Relevance | 7 | Directly informs patient selection and prognosis counseling for combination ICI in rare tumors |
| Population Reach | 4 | Rare cancers individually small; collectively important; lung+liver metastases subset is a clinically meaningful subgroup |
| Implementation Speed | 6 | Prognostic information is immediately usable in clinical counseling without regulatory action |
| Evidence Strength | 5 | Retrospective; multi-tumor type heterogeneity is a major confounder; NCI/SWOG affiliation adds institutional rigor |
- Key quantitative result: Combined lung and liver metastases associated with shorter PFS and OS with anti-CTLA-4 + anti-PD-1 (specific HR not available from abstract)
- External validation: No independent external validation; NCI/SWOG multicenter design offers some internal generalizability
- Main limitation: Retrospective design; heterogeneous rare tumor population; confounding by tumor type, prior therapy, and performance status not fully detailed in abstract
- Equity implications: Rare cancer patients are often systematically excluded from trials; this dataset addresses an underserved population with limited treatment evidence
- Evidence Maturity (revised): Validated (confirmed — prospective trial data retrospectively analyzed)
Article 11 — Cardiovascular Disease and GDMT in Low-SES Patients (PMID: 42999919)
⚪ PROMISING_PRELIMINARY | Single-Center Observational | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | The gap in GDMT receipt for low-SES patients is well-documented; single-center data adds limited new insight |
| Clinical Relevance | 6 | Actionable for policymakers and health systems; identifies a persistent care gap |
| Population Reach | 7 | Low-SES populations represent a large global burden; cardiovascular disparities are a major public health concern |
| Implementation Speed | 5 | Policy-level change is slow; targeted intervention programs could be faster |
| Evidence Strength | 4 | Single-center, unspecified study design; medium classification confidence |
- Key quantitative result: HFrEF > HFpEF (63.6% vs. reported comparator); GDMT prevalence reported per CVD type (specific rates not available from abstract)
- External validation: None — single center
- Main limitation: Single-center; study design unspecified; unknown if findings are representative of low-SES populations broadly
- Equity implications: Directly addresses underserved populations; findings should motivate policy action on cardiovascular care access
- Evidence Maturity (revised): Exploratory (downgraded — single center, design unspecified)
Article 12 — QoL and Caregiver Burden in Metachromatic Leukodystrophy (MLD) (PMID: 43000417)
⬜ Standard | Observational Study | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | MLD caregiver burden is understudied; Polish registry provides regional data with limited generalizability |
| Clinical Relevance | 5 | Supports case for early detection and coordinated care; relevant for gene therapy rollout planning (atidarsagene autotemcel approved) |
| Population Reach | 3 | MLD affects ~1–2 per 100,000 live births; very small absolute population, but high unmet need |
| Implementation Speed | 5 | Findings could immediately inform care coordination models and advocacy priorities |
| Evidence Strength | 4 | Observational; small population typical for ultra-rare disease; exploratory interpretation recommended |
- Key quantitative result: None quantified in abstract; caregiver burden and QoL characterized qualitatively
- External validation: None
- Main limitation: Small sample typical of ultra-rare disease; Poland-specific findings may not generalize; abstract-only access
- Equity implications: Rare disease patients face systematic under-diagnosis and inadequate support; caregiver burden is an underrecognized equity issue
- Evidence Maturity (revised): Exploratory (confirmed)
Article 13 — LC-MS/MS Method for Alectinib and M4 Quantification (PMID: 43000705)
⬜ Standard | Analytical Validation | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Alectinib TDM is clinically relevant; a validated micro-volume plasma method addresses a practical gap |
| Clinical Relevance | 5 | Enables therapeutic drug monitoring (TDM) in ALK+ NSCLC, particularly in patients with limited blood volume (pediatric, elderly, frail) |
| Population Reach | 4 | ALK+ NSCLC represents ~3–5% of NSCLC; meaningful niche but not broad population |
| Implementation Speed | 5 | Analytical method validation is a prerequisite — could be adopted by clinical labs relatively quickly |
| Evidence Strength | 7 | Full analytical validation per regulatory standards (selectivity, linearity, matrix effects, stability, carryover) |
- Key quantitative result: Full validation parameters met across analytical performance criteria (specific LLOQs and linearity ranges not available from abstract)
- External validation: Standard regulatory validation framework applied
- Main limitation: Plasma-only method; clinical utility of TDM for alectinib outcomes not demonstrated in this study
- Equity implications: Limited-volume method benefits pediatric patients and others requiring minimally invasive sampling
- Evidence Maturity (revised): Validated (confirmed — full analytical validation)
Article 14 — Perinatal Mental Health in Women With/Without Gestational Diabetes (PMID: 43000942)
⬜ Standard | Prospective Cohort | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Differential mental health risk by GDM status and ethnicity adds nuance to existing literature |
| Clinical Relevance | 6 | Actionable for obstetric screening protocols; mental health in GDM patients is under-screened |
| Population Reach | 7 | GDM affects ~14% of pregnancies globally; mental health comorbidity is a major public health concern |
| Implementation Speed | 6 | Screening modifications could be implemented relatively quickly in antenatal care settings |
| Evidence Strength | 6 | Prospective cohort from a large trial (GEMS); multi-ethnic; abstract-only limits full assessment |
- Key quantitative result: Non-European ethnicity, obesity, and maternal age associated with poor mental health at different magnitudes and time points in GDM vs. non-GDM groups
- External validation: GEMS Trial cohort is a well-characterized dataset
- Main limitation: Abstract-only; specific effect sizes and time points not detailed; causality not established
- Equity implications: Non-European ethnicity and obesity identified as specific risk factors — directly relevant to underserved minority populations who face compounded barriers to mental health care
- Evidence Maturity (revised): Exploratory (confirmed — prospective but hypothesis-generating)
Article 15 — CVD Risk Distribution in Hypertensive Adults in Bangladesh (PMID: 43001077)
⬜ Standard | Observational | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | CVD risk mapping in Bangladesh provides locally relevant data; methodology is standard |
| Clinical Relevance | 5 | Spatial risk mapping supports resource allocation for prevention programs |
| Population Reach | 6 | Bangladesh has 170M+ people; hypertensive adults are a large and high-risk subgroup |
| Implementation Speed | 5 | Population-level prevention requires policy action and health system strengthening |
| Evidence Strength | 5 | BDHS 2022 national survey data; large and representative; CVD risk estimated, not measured |
- Key quantitative result: Older age, female sex, overweight/obesity, tobacco use, higher wealth associated with higher predicted CVD risk
- External validation: National survey; no external validation of risk estimates
- Main limitation: Predicted (not measured) CVD risk; risk calculator assumptions may not fully apply to Bangladeshi population
- Equity implications: Bangladesh is a lower-middle-income country with limited CVD prevention infrastructure; study could directly inform targeted resource allocation
- Evidence Maturity (revised): Exploratory (confirmed)
Article 16 — Periodontitis and Ischemic Heart Disease Association (PMID: 43001111)
⬜ Standard | Observational | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Periodontitis-CVD link is well-explored; shared risk factor analysis adds limited novelty |
| Clinical Relevance | 5 | Dental health as a CVD risk factor remains underintegrated into cardiology practice |
| Population Reach | 7 | Periodontitis affects ~50% of adults globally; IHD is the leading cause of death |
| Implementation Speed | 5 | Clinical integration of dental screening in cardiology is feasible but requires interdisciplinary coordination |
| Evidence Strength | 5 | Representative US adult sample; multivariable adjustment attenuates association — shared risk factors complicate causal inference |
- Key quantitative result: Association attenuated after multivariable adjustment; potential mediation by shared risk factors (specific ORs not available from abstract)
- External validation: None reported
- Main limitation: Cross-sectional/observational; confounding by shared risk factors; causality not established
- Equity implications: Dental care access is strongly socioeconomically stratified; low-income populations have both higher periodontitis rates and higher CVD risk
- Evidence Maturity (revised): Exploratory (confirmed — association study, causality not established)
Article 17 — Levacetylleucine for Niemann-Pick Disease Type C (PMID: 43001446)
⬜ Standard | Narrative Review | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Levacetylleucine represents a genuinely novel therapeutic mechanism for NPC; positions as "foundational" treatment |
| Clinical Relevance | 7 | NPC has extremely limited treatment options; levacetylleucine has regulatory approval in some jurisdictions |
| Population Reach | 2 | NPC affects ~1 in 120,000–150,000 live births — ultra-rare; scored relative to unmet need in this population |
| Implementation Speed | 5 | Drug is available/approved in some regions; adoption depends on diagnosis rates and access |
| Evidence Strength | 3 | Narrative review only; no primary trial data reported |
- Key quantitative result: None — narrative synthesis
- External validation: Levacetylleucine has prior Phase II data (ACORN trial); this review contextualizes without generating new evidence
- Main limitation: Narrative review; no graded evidence synthesis; abstract-only
- Equity implications: Ultra-rare disease patients face extreme diagnostic delay (average 5–10 years); access to levacetylleucine will be highly unequal globally
- Evidence Maturity (revised): Exploratory (confirmed — narrative review summarizing existing evidence)
Article 18 — CRC Screening Beliefs and Health-Seeking Behavior in Türkiye (PMID: 43001524)
⬜ Standard | Observational | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Health beliefs and screening behavior links are well-established; country-specific data has limited novelty |
| Clinical Relevance | 5 | Informs public health communication strategies for CRC screening in Turkey |
| Population Reach | 5 | CRC is globally the third most common cancer; Turkish population is 85M+ |
| Implementation Speed | 7 | Findings directly applicable to health communication campaigns |
| Evidence Strength | 4 | Observational; hospitalized adults are not representative of the general population; design unspecified beyond cross-sectional |
- Key quantitative result: Screening beliefs (perceived benefits, confidence) and education independently associated with health-seeking behavior (specific ORs not available)
- External validation: None
- Main limitation: Hospitalized patient sample introduces major selection bias; not representative of community-dwelling adults
- Equity implications: Educational level as an independent predictor highlights literacy and education as modifiable equity targets for CRC screening uptake
- Evidence Maturity (revised): Exploratory (confirmed)
Article 19 — AI in Pediatric Hospital Medicine: Review (PMID: 43001824)
⬜ Standard | Narrative Review | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | General narrative on AI in pediatric medicine; no new primary findings |
| Clinical Relevance | 5 | Provides useful framing for clinical leaders in pediatric hospital medicine |
| Population Reach | 6 | Pediatric hospital medicine is universal; AI applications could benefit all hospitalized children |
| Implementation Speed | 4 | AI tools in pediatric medicine face significant validation, regulatory, and equity barriers |
| Evidence Strength | 2 | Narrative review; no primary data; no systematic methodology |
- Key quantitative result: None
- External validation: None
- Main limitation: Entirely narrative; risk of selection bias in evidence cited
- Equity implications: AI tools trained on adult or majority-population data may perform poorly in pediatric or minority populations
- Evidence Maturity (revised): Exploratory (confirmed)
Article 20 — Gait Impairment and Incident Dementia: Age-Dependent Association (PMID: 43002715)
⬜ Standard | Prospective Cohort | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Age-dependent nonlinear gait-dementia relationship is a nuanced and clinically significant finding |
| Clinical Relevance | 7 | Gait assessment is feasible in any clinical setting; could refine dementia screening in younger-old adults |
| Population Reach | 8 | 55 million people live with dementia globally; gait assessment is universally accessible |
| Implementation Speed | 7 | POMA gait assessment requires no technology investment; could be integrated into routine clinical visits |
| Evidence Strength | 6 | Prospective cohort, 6.2-year follow-up, Korean LSCD study; well-characterized sample; single-country, single-ethnic group limits generalizability |
- Key quantitative result: Gait impairment predicts incident dementia most strongly in younger-old adults; nonlinear relationship with age (specific HRs not available from abstract)
- External validation: None — Korean population only
- Main limitation: Single-country (Korean) prospective cohort; POMA is a clinician-rated scale with potential inter-rater variability; ethnicity-specific results limit global generalizability
- Equity implications: Gait assessment is low-cost and equipment-free — highly suitable for low-resource settings; benefits older adults who lack access to neuroimaging
- Evidence Maturity (revised): Exploratory (confirmed — prospective but single-country, findings need replication in other populations)
Article 21 — Genistein Supplementation for MCI Due to Alzheimer Disease: Protocol (PMID: 43002725)
⬜ Standard | Study Protocol | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Phytoestrogen/genistein in AD is a plausible and interesting hypothesis; protocol publication adds no results |
| Clinical Relevance | 3 | Protocol only — no results yet; clinical relevance contingent on outcome |
| Population Reach | 8 | MCI-to-AD conversion affects millions globally; any effective prevention would be transformative |
| Implementation Speed | 2 | Trial ongoing until January 2029; translation timeline is 5–10+ years minimum |
| Evidence Strength | 2 | Protocol only; no data |
- Key quantitative result: None — protocol publication
- External validation: N/A
- Main limitation: No results; soy isoflavone supplementation trials have mixed historical record for cognitive outcomes
- Equity implications: Oral genistein supplement is low-cost — high equity potential IF effective
- Evidence Maturity (revised): Exploratory (confirmed — protocol only)
Article 22 — Migalastat vs. ERT in Treatment-Naïve Fabry Disease (followME Registry) (PMID: 43003395)
🟡 UNDERSERVED_POPULATION | Prospective Registry | Triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Real-world head-to-head comparison of migalastat vs. ERT in treatment-naïve Fabry patients is clinically valuable |
| Clinical Relevance | 8 | Directly informs treatment choice between oral and IV therapy in Fabry disease; oral option has major quality-of-life implications |
| Population Reach | 3 | Fabry disease is rare (~1 in 40,000); scored relative to disease population and high unmet need |
| Implementation Speed | 6 | Migalastat is already approved; registry evidence could influence formulary and guideline decisions |
| Evidence Strength | 5 | Prospective registry; non-randomized; observational confounding cannot be excluded; abstract-only |
- Key quantitative result: FACE rates per 1000 person-years compared (specific rates not available from abstract); multisystemic effectiveness of migalastat supported
- External validation: Ongoing registry; no independent external cohort
- Main limitation: Registry (non-randomized); patient selection bias (migalastat only approved for amenable variants); abstract-only
- Equity implications: Oral migalastat vs. biweekly IV infusion has profound quality-of-life and access equity implications for Fabry patients in lower-resource settings
- Evidence Maturity (revised): Exploratory (downgraded — prospective registry, non-randomized; real-world evidence but confounded)
Articles 23–46 — Abbreviated Assessments
| # | PMID | Title (Short) | Scientific Novelty | Clinical Relevance | Population Reach | Impl. Speed | Evidence Strength | Evidence Maturity |
|---|---|---|---|---|---|---|---|---|
| 23 | 42999628 | Atezolizumab dose-outcomes (Phase I) | 4 | 5 | 5 | 5 | 4 | Exploratory |
| 24 | 43000203 | CAR-T apheresis algorithm (ACIT001) | 5 | 6 | 4 | 5 | 4 | Exploratory |
| 25 | 43000212 | Tsukushi predicts sarcopenia | 6 | 5 | 6 | 4 | 6 | Validated |
| 26 | 43001486 | Liquid biopsy for brain tumors (review) | 4 | 5 | 5 | 3 | 2 | Exploratory |
| 27 | 43002336 | Physical performance post-MI (review) | 3 | 5 | 6 | 4 | 2 | Exploratory |
| 28 | 43002474 | Adenosine A2AR in cancer immunotherapy (review) | 5 | 4 | 6 | 2 | 2 | Exploratory |
| 29 | 43002606 | Amyloidogenic vs. innocent light chains | 5 | 6 | 4 | 4 | 4 | Exploratory |
| 30 | 43002639 | Redefining success in cancer care (review) | 4 | 5 | 7 | 4 | 2 | Exploratory |
| 31 | 43002657 | eHealth literacy in geriatric patients | 4 | 4 | 5 | 4 | 4 | Exploratory |
| 32 | 43002727 | MGNS diagnosis/management framework | 4 | 6 | 4 | 5 | 3 | Exploratory |
| 33 | 43002730 | DVRd PFS modeling in multiple myeloma | 4 | 5 | 5 | 4 | 4 | Exploratory |
| 34 | 43002894 | Pterostilbene + osimertinib in NSCLC | 5 | 3 | 5 | 2 | 4 | Exploratory |
| 35 | 43003129 | LVAD care literature mapping | 3 | 4 | 4 | 3 | 3 | Exploratory |
| 36 | 43003172 | Rheumatology-oncology Delphi consensus | 4 | 6 | 5 | 5 | 3 | Exploratory |
| 37 | 43003180 | Ocular surface photography for AI | 5 | 5 | 6 | 3 | 2 | Exploratory |
| 38 | 43003441 | Nanotech drug delivery for retinoblastoma | 5 | 4 | 3 | 2 | 2 | Exploratory |
| 39 | 43003546 | Predictive analytics in ICU medications | 4 | 6 | 6 | 4 | 2 | Exploratory |
| 40 | 43003711 | LLM vs. surgeons in hernia management | 5 | 5 | 5 | 5 | 4 | Exploratory |
| 41 | 42999387 | Phenotypic clustering in end-stage liver disease | 4 | 5 | 4 | 4 | 4 | Exploratory |
| 42 | 42999685 | ML for prostate radiotherapy toxicity | 4 | 5 | 5 | 4 | 4 | Exploratory |
| 43 | 42999851 | Disaster nephrology 2050 simulation | 3 | 4 | 5 | 2 | 2 | Exploratory |
| 44 | 43002260 | Y-shaped DNA walker for ctDNA detection | 5 | 2 | 4 | 2 | 3 | Exploratory |
| 45 | 42999547 | Langerhans cell histiocytosis in child (case) | 2 | 3 | 2 | 3 | 2 | Exploratory |
| 46 | 43003323 | Social needs screening at mammography | 4 | 6 | 6 | 6 | 4 | Exploratory |